For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260316:nRSP7887Wa&default-theme=true
RNS Number : 7887W Medpal AI PLC 16 March 2026
16 March 2026
MedPal AI plc
("MedPal AI" or the "Company")
Pharmacy - Operational Update
MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health
company, is pleased to provide an operational update on pharmacy dispensing
volumes at its wholly-owned subsidiary, MedPal Limited.
MedPal AI combines its user-friendly mobile app, AI-driven diagnosis and
triage with human-in-the-loop clinical oversight and prescribing services,
with high-tech robotic pharmacy dispensing.
Dispensing Performance
Since the launch of pharmacy operations at the Company's national distribution
centre in November 2025, MedPal Limited has dispensed a total of almost
147,000 prescription items in the first four months of operations, generating
turnover in the period in excess of £1.5 million.
The average gross margin across the period was approximately 33%, reflecting
the Company's efficient, technology-driven fulfilment model and favourable
unit economics as prescription volumes continue to scale.
In February 2026, the Company dispensed 32,637 items, maintaining a strong
level of activity and continuing to support monthly pharmacy revenue in excess
of £300,000.
This sustained growth in dispensing volumes further demonstrates the
effectiveness of the Company's advanced AI triage system and state-of-the-art
robotic dispensing infrastructure, together with increasing patient demand for
both NHS and private prescription services, including through the
MedPal.clinic weight-loss platform
Jason Drummond, CEO of MedPal AI, said:
"Dispensing nearly 147,000 prescription items and generating turnover in
excess of £1.5 million in our first four months of pharmacy operations is an
outstanding achievement for the Company. This performance validates the
scalability and commercial viability of our automated dispensing model and the
strength of our vertically integrated platform.
"We continue to see strong demand across both our NHS Distance Selling
Pharmacy contract and our private weight-loss services through MedPal.clinic,
and we look forward to updating the market on continued progress."
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer Via Square1 Consulting
Cairn Financial Advisers LLP +44 (0) 20 7213 0880
Louise O'Driscoll/Jo Turner
Clear Capital Markets Limited +44 (0) 20 3869 6080
Bob Roberts
Square1 Consulting +44 (0) 20 7929 5599
David Bick +44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDJFMLTMTJBMIF
Copyright 2019 Regulatory News Service, all rights reserved